Chinese web services company, Baidu, has partnered with two biggest online travel companies in the country to become the leading player in the race for China’s travelers. There are reports that the search engine giant has already lapped its Chinese rivals, including Alibaba.
Earlier, Baidu sold stake in Qunar to rival Ctrip. Now, the search engine giant will have 25% stake in the country’s biggest travel site Ctrip, which will take about 48% stake Qunar. Experts believed that the deal will be beneficial for both the companies that were previously fighting for price war.
The below 50% ownership will also allow Ctrip to get protection against scrutiny from Chinese antitrust authorities. Earlier, the company acquired more than one third stakes in its rival, eLong.
After the new deal, Ctrip will start cooperating closely with the search engine giant, which could help in generating traffic for Ctrip. Chi Tsang, analyst at HSBC, said, “The pact also spells relief for Baidu investors, who have recently fretted about shrinking margins. Divesting most of its stake in loss-making Qunar will boost Baidu’s margins by six to seven percentage points”.
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan